Buy Cibinqo for 75% US drug prices. European product.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for Europe: Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1 79090 Freiburg Germany
Information about Cibinqo (Abrocitinib)
Cibinqo (Abrocitinib) is a prescription medication used to treat moderate to severe atopic dermatitis (eczema) in adults and adolescents aged 12 and older who have not responded well to other treatments. It is a Janus kinase (JAK) inhibitor that works by targeting specific enzymes involved in the inflammatory process, helping to reduce symptoms such as itching, redness, and rash.
Product Highlights:
- Cibinqo is used to treat moderate to severe atopic dermatitis (eczema) in adults and pediatric patients aged 12 years and older who have not responded adequately to other treatments.
Key Ingredient
Key Benefits
- Provides relief for individuals with moderate to severe atopic dermatitis, especially those who have not found relief from other treatments.
- Helps to reduce itching, redness, and rash associated with eczema.
- Available as oral tablets, which can be taken with or without food, offering an alternative to topical treatments.
Direction of Use
- Typically administered as 100 mg or 200 mg tablets once daily. The specific dose should be determined by a healthcare provider based on individual patient needs and response to treatment.
- Take the tablet orally, with or without food, according to the prescribed regimen.
Safety Concerns
- May include headache, nausea, upper respiratory infections, and increased levels of liver enzymes.
- Potential risks include higher susceptibility to infections, elevated cholesterol levels, liver issues, and, in rare cases, increased risk of certain cancers and blood clots.
- Regular monitoring may be necessary to assess liver function, cholesterol levels, and overall health to manage and mitigate risks associated with long-term use.
Avoid Cibinqo (Abrocitinib) If
- Cibinqo should not be used in individuals with severe hepatic impairment.
- Avoid use if you have active infections or a history of frequent infections, as JAK inhibitors can increase the risk of serious infections.
- Cibinqo may not be suitable for patients with a history of specific cancers due to an increased risk of malignancies.
- Do not use if you have a known hypersensitivity to abrocitinib or any component of the medication.
